Status: Recruiting
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Participants needed: 30
Trial details
Phase: Phase 3Age: 2-17Biological sex: AllType: InterventionalSponsor: OctapharmaUpdated: Jun 6, 2025Locations: 6
Eligibility criteria
Age ≥2 years and ≤17 years. [+3]
Patients with previously diagnosed CIDP who lack any CIDP symptoms. [+14]